Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

NCT ID: NCT02268253

Last Updated: 2025-01-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 82 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-10
• Study Completion Date: 2023-03-27

Brief Summary

This multicenter, multi-arm trial evaluated the safety and efficacy of tagraxofusp, a cell division cycle protein 123 homolog-targeted therapy, in participants with either CMML or MF. There were 2 CMML cohorts, 1 enrolled participant with CMML (CMML-1 or CMML-2) who were refractory/resistant or intolerant to hypomethylating agents (HMA), hydroxyurea (HU), or intensive chemotherapy and 1 enrolled treatment-naive participants with CMML (CMML-1 or CMML-2) with molecular features associated with poor prognosis. The MF cohort enrolled participants who were resistant/refractory or intolerant to approved Janus kinase (JAK) therapy (JAK1/JAK2 or JAK2).

Detailed Description

This was a non-randomized, open-label, multicenter study, divided into 3 stages.

Stage 1: Stage 1 of the study was to enroll participants with CMML, MF, advanced systemic mastocytosis, or advanced symptomatic primary eosinophilic disorder.

Stage 2: Stage 2 was to enroll MF and CMML participants.

Stage 3A: Stage 3A was to enroll 2 populations of participants with CMML, those with CMML-1 or CMML-2 who were refractory/resistant/intolerant to HMAs, HU, or intensive chemotherapy (relapsed/refractory participants); and participants with treatment-naïve CMML-1 or CMML-2 (previously untreated participants) with molecular features associated with a poor prognosis.

Conditions

Myelofibrosis; Chronic Myelomonocytic Leukemia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose Level 1 - Tagraxofusp - 7 micrograms/kilogram (µg/kg)/day - Chronic Myelomonocytic Leukemia

Group Type: EXPERIMENTAL

Tagraxofusp Injection

Intervention Type: DRUG

Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.

Dose Level 2 - Tagraxofusp - 9 µg/kg/day - Chronic Myelomonocytic Leukemia

Group Type: EXPERIMENTAL

Tagraxofusp Injection

Intervention Type: DRUG

Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.

Dose Level 3 - Tagraxofusp - 12 µg/kg/day - Chronic Myelomonocytic Leukemia

Group Type: EXPERIMENTAL

Tagraxofusp Injection

Intervention Type: DRUG

Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.

Dose Level 1 - Tagraxofusp - 7 µg/kg/day - Myelofibrosis

Group Type: EXPERIMENTAL

Tagraxofusp Injection

Intervention Type: DRUG

Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.

Dose Level 2 - Tagraxofusp - 9 µg/kg/day - Myelofibrosis

Group Type: EXPERIMENTAL

Tagraxofusp Injection

Intervention Type: DRUG

Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.

Dose Level 3 - Tagraxofusp - 12 µg/kg/day - Myelofibrosis

Group Type: EXPERIMENTAL

Tagraxofusp Injection

Intervention Type: DRUG

Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.

Interventions

Tagraxofusp Injection

Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.

Intervention Type: DRUG

Other Intervention Names

SL-401; Elzonris

Eligibility Criteria

Inclusion Criteria

All Participants - Participants meeting all the following criteria were considered for enrollment:

1. The participant had a life expectancy of > 6 months.

2. The participant had an Eastern Cooperative Oncology Group performance status of 0-2.

3. The participant had adequate baseline organ function, including cardiac, renal, and hepatic function:

• Left ventricular ejection fraction 2: institutional lower limit of normal as measured by multigated acquisition scan or 2-dimensional echocardiogram within 28 days prior to the start of therapy and no clinically significant abnormalities on a 12-lead electrocardiogram.
• Serum creatinine ≤ 1.5 milligrams/deciliter (dL).
• Serum albumin ≥ 3.2 grams (g)/dL (or 32 g/liter [L]) in the absence of receipt of intravenous albumin within the previous 72 hours.
• Aspartate transaminase and alanine transaminase ≤ 2.5 times the upper limit of normal (ULN).
• Creatine phosphokinase ≤ 2.5 times the ULN.
• Absolute neutrophil count ≥ 0.5×10^9/L.

4. If a woman of child-bearing potential, the participant had a negative serum or urine pregnancy test within 1 week prior to tagraxofusp treatment (intervals shorter than 1 week are acceptable, if required by institutional guidelines).

5. The participant (either male or female) agrees to use acceptable contraceptive methods for the duration of time in the study, and to continue to use acceptable contraceptive methods for 1 week after the last tagraxofusp infusion.

6. The participant can adhere to the study visit schedule and other protocol requirements, including follow-up for response assessments.

Myelofibrosis (Stage 2) - Participants with MF meeting all of the following criteria, in addition to those specified for all participants, above, are eligible for enrollment in Stage 2:

1. Participant meets the 2016 World Health Organization (WHO) diagnostic criteria for MF and has an International Prognostic Scoring System/Dynamic International Prognostic Scoring System (IPSS/DIPSS)/DIPSS-plus intermediate-2 or high-risk disease. Participants with IPSS/DIPSS/DIPSS-plus low or intermediate-1 risk disease who have at least 1 of the following symptoms are also eligible: MF-related anemia (hemoglobin < 10 g/dL), splenomegaly (palpable size > 10 centimeters), leukocytosis (white blood cell count [WBC] > 25×10^9/L), marked thrombocytosis (platelet count > 1,000×10^9/L), or constitutional symptoms (weight loss > 10%, during prior 6 months or fever [> 37.5 degrees Celsius or drenching night sweats for > 6 weeks]), as recommended by the European LeukemiaNet/International Working Group (ELN/IWG) 2018 criteria.

2. Participant was approved JAK therapy (JAK1/JAK2 or JAK2) resistant/refractory or intolerant, in accordance with the ELN/IWG 2018 criteria, and at least 4 weeks have elapsed between the last dose of any MF-directed drug treatments, excluding HU, and study enrollment (first dose). HU can be continued until 2 weeks prior to study enrollment.

3. Participant was not eligible for an immediate allogeneic-stem cell transplantation.

CMML (Stage 3A):

4. Participant had a 2016 WHO-defined diagnosis of CMML (persistent monocytosis ≥ 1×10^9/L for at least 3 months, with other causes excluded, and monocytes ≥10% of WBC in peripheral blood, no criteria and no previous history of CMML, essential thrombocythemia, polycythemia vera, and acute promyelocytic leukemia; if eosinophilic, neither platelet-derived growth factor receptor A, platelet-derived growth factor receptor beta, fibroblast growth factor receptor 1 rearrangements nor pericentriolar material 1-JAK2 translocation; < 20% blasts in peripheral blood and bone marrow aspirate; > 1 following criteria: dysplasia in > 1 myeloid lineage, acquired clonal cytogenetic or molecular abnormality in hematopoietic cells).

5. Participant had 2016 WHO-defined CMML-1 (2-4% blasts in peripheral blood and/or 5-9% blasts in bone marrow) and CMML-2 (5-19% blasts in peripheral blood and/or 10-19% blasts in bone marrow, and/or presence of Auer rods).

6. Participant was refractory/resistant/intolerant, as defined for the purposes of this study (in the absence of a standard definition for CMML) below, to HMAs, HU, or intensive chemotherapy, including:

• Resistance/intolerance to HU is defined as:

• Uncontrolled myeloproliferation, (platelets > 400×10^9/L and WBC > 10×10^9/L after 3 months of at least 2 g/day of HU); or
• Myelosuppression at a clinically relevant dose; or
• Presence of unacceptable HU-related non-hematological toxicities, such as mucocutaneous manifestations, gastrointestinal symptoms, pneumonitis, or fever at any dose of HU.
• Conventional definition for HMA failure is defined for the purposes of this study (in the absence of a standard definition for CMML) as:

• Disease progression following at least 4 to 6 cycles of 5-azacitidine or decitabine; or
• Relapse after achieving response; or
• Intolerance to 5-azacitidine or decitabine at the prescribed dose.

or

• Participant was classified as high-risk based on the presence of morphological features, as described by the 2016 WHO prognostic system, and the clinical and molecular features described in molecularly integrated prognostic systems, such as the Groupe Français des Myélodysplasies, Mayo Molecular Model, and the CMML specific prognostic model and thus is not expected to benefit from HMAs.

7. Participant was ineligible for an immediate allogeneic stem cell transplantation (allo-SCT).

7. Participant had clinically significant cardiovascular disease (for example, uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina, or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).

8. Participant had uncontrolled, clinically significant pulmonary disease (for example, chronic obstructive pulmonary disease, pulmonary hypertension) that, in the Investigator's opinion, would have put the participant at significant risk for pulmonary complications during the study.

9. Participant had known active or suspected disease involvement of the central nervous system (CNS). If suspected due to clinical findings, CNS disease was to be ruled out with relevant imaging and/or examination of cerebrospinal fluid.

Exclusion Criteria

1. Participant had persistent clinically significant toxicities Grade ≥2 from previous therapies, including cytotoxic chemotherapy, targeted therapies, biological therapies, or immunotherapies, not readily controlled by supportive measures (excluding alopecia, nausea, and fatigue).

2. Participant received treatment with any disease-related therapy, including radiation therapy within 14 days of study entry.

3. Participant received an allo-SCT within 3 months of study entry.

4. Participant received treatment with another investigational agent within 14 days of study entry or concurrent treatment with another investigational agent.

5. Participant previously received treatment with tagraxofusp or has a known hypersensitivity to any components of the drug product.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stemline Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of California, San Francisco

Clovis, California, United States

City of Hope

Duarte, California, United States

University of California, Los Angeles

Los Angeles, California, United States

Stanford Cancer Institute

Stanford, California, United States

Mayo Clinic Florida

Jacksonville, Florida, United States

Georgia Cancer Center at Augusta University

Augusta, Georgia, United States

Rush University Medical Center

Chicago, Illinois, United States

Indiana Blood and Bone Marrow Transplantation

Indianapolis, Indiana, United States

University of Kansas Cancer Center

Westwood, Kansas, United States

Norton Cancer Institute

Louisville, Kentucky, United States

Dana Farber Cancer Institute (DFCI)

Boston, Massachusetts, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Michigan Health System

Ann Arbor, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

John Theurer Cancer Center

Hackensack, New Jersey, United States

University of New Mexico

Albuquerque, New Mexico, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

Weill Cornell Medical Center

New York, New York, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

The Ohio State University

Columbus, Ohio, United States

MD Anderson Cancer Center

Houston, Texas, United States

Huntsman Cancer Institute

Salt Lake City, Utah, United States

University of Alberta

Edmonton, Alberta, Canada

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Countries

United States; Canada

References

Yacoub A, Ali H, Gupta V, Wang ES, Patnaik MM, Schiller GJ, Taparia M, Mughal TI, Lindsay R, Galleu A, Gupta I, Pemmaraju N. Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis. Blood Neoplasia. 2025 Aug 25;2(4):100165. doi: 10.1016/j.bneo.2025.100165. eCollection 2025 Nov.

Reference Type: DERIVED

PMID: 41146971 (View on PubMed)

Patnaik MM, Ali H, Wang ES, Yacoub A, Foran JM, Gupta V, Schiller GJ, Stevens DA, Talpaz M, Wall S, Lasho TL, Mangaonkar AA, Badar T, Lindsay R, Galleu A, Gupta I, Pemmaraju N, Garcia-Manero G. Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study. Blood Neoplasia. 2025 May 11;2(4):100115. doi: 10.1016/j.bneo.2025.100115. eCollection 2025 Nov.

Reference Type: DERIVED

PMID: 40919483 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

STML-401-0314

Identifier Type: -

Identifier Source: org_study_id